<DOC>
	<DOC>NCT02777008</DOC>
	<brief_summary>Single- and multiple-ascending dose study of CTP-543 in healthy volunteers.</brief_summary>
	<brief_title>Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects</brief_title>
	<detailed_description>This two-part study will assess, in healthy volunteers, under fasted conditions, and in a sequential manner, the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single- and multiple-ascending doses of CTP-543.</detailed_description>
	<criteria>Healthy adult males and females between 18 and 50 years of age, inclusive Body weight â‰¥ 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive History of clinically significant central nervous system (eg, seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions PR interval &gt; 220 msec or QRS duration &gt; 120 msec or QTcF interval &gt; 450 msec obtained at screening visit or prior to the first dose of study drug History of herpes zoster Hemoglobin, white blood cell, or platelet levels below the lower reference limit at screening or prior to the first dose of study drug Liver function tests greater than the upper limit of normal Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody Urinalysis positive for protein or glucose A positive screen for alcohol, drugs of abuse, or tobacco use Donation of blood, plasma or other blood products prior to screening A positive tuberculosis test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>